Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV74BT
|
|||
| Drug Name |
Samuraciclib
|
|||
| Synonyms |
Samuraciclib; ICEC0942; CT7001; ICEC-0942; ICEC0942 free base; 1805833-75-3; CT-7001; 46D4HS9ODA; 1805833-75-3 (free base); Samuraciclib HCl; (3~{R},4~{R})-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol; (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol; 3-Piperidinol, 4-(((3-(1-methylethyl)-7-((phenylmethyl)amino)pyrazolo(1,5-a)pyrimidin-5-yl)amino)methyl)-, (3R,4R)-; ICEC 0942; (3r,4r)-4-[[[7-[(Phenylmethyl)amino]-3-Propan-2-Yl-Pyrazolo[1,5-A]pyrimidin-5-Yl]amino]methyl]piperidin-3-Ol; 3-Piperidinol, 4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-, (3R,4R)-; Samuraciclib di-HCl; CT7001 di-HCl; SAMURACICLIB [INN]; UNII-46D4HS9ODA; CT-7001 di-HCl; CT7001 HCl; SAMURACICLIB [WHO-DD]; CT-7001 HCl; GTPL9903; CHEMBL4297488; SCHEMBL17032274; EX-A3445; BDBM50526797; NSC832261; NSC835588; NSC-832261; NSC-835588; HY-103712; (3R,4R)-4-((7-(benzylamino)-3-isopropylpyrazolo[1,5-a]pyrimidin-5-ylamino)methyl)piperidin-3-ol dihydrochloride; (3R,4R)-4-({[7-(benzylamino)-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}methyl)piperidin-3-ol; 3-Piperidinol,4-[[[3-(1-methylethyl)-7-[(phenylmethyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]-,(3R,4R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1/2 | [1] | |
| Company |
Carrick Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30N6O
|
|||
| Canonical SMILES |
CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NCC4CCNCC4O
|
|||
| InChI |
InChI=1S/C22H30N6O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27)/t17-,19+/m1/s1
|
|||
| InChIKey |
YCVGLKWJKIKVBI-MJGOQNOKSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04802759) A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER). U.S.National Institutes of Health. | |||
| REF 2 | The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.